Health Canada safety review finds link between the use of Xeljanz and Xeljanz XR (tofacitinib) and increased risk of serious heart-related issues and cancer
Product safety
Read the official notice →- Date
- 2022-01-12
- Country
- Canada
- Product
- Xeljanz and Xeljanz XR (tofacitinib), a prescription drug used to treat rheumatoid arthritis, psoriatic arthritis and…
- Category
- Drugs & medical
- Source
- Health Canada
Copied automatically from the Government of Canada. Details may be shortened or out of date; the official notice is the authoritative source. Disclaimer
What to do
- Check the product name, strength and lot number against the official notice.
- Do not stop a prescribed medicine without talking to your doctor or pharmacist first.
- Ask the pharmacy or supplier about a replacement or refund.
General guidance from Recall Atlas. The official notice from the Government of Canada has the exact models, batch codes and remedy, and it takes priority.
Other drugs & medical recalls in Canada
- 2022-01-17
CA- CA
- CA
PAXLOVID (nirmatrelvir and ritonavir) - Dosing and Dispensing in Renal Impairment, Risk of Serious Adverse Reactions Due to Drug Interactions, and English-Only Labels
Labelling - New safety information - Supply - COVID
Health CanadaOfficial notice → - 2022-01-11
- CA
Shelf Life Extension for the SPIKEVAX (elasomeran) COVID-19 Vaccine with Printed Expiry Dates on Vial and Carton Labels
Labelling - Packaging - Product safety - Supply
Health CanadaOfficial notice → - 2022-01-10
- CA
- CA
Duramatrix-Onlay ® Collagen Dura Substitute Membrane
Labelling and packaging
Health CanadaOfficial notice →